Levetiracetam – An Alternative Option in Preterm Neonates for Acute Seizure Management

800x600 Neonatal seizures occur in five of 1000 live births in North America and affect the future development of the child. Preterm neonates are more susceptible to seizures due to brain immaturity with the incidence of 11 of 1000 live births, much higher than neonatal seizures. Few medicines studied and approved to treat this subset of patients, management difficult. The only medicines approved by the FDA are phenytoin and Phenobarbital in the neonatal period. Failure of these agents due to lack of efficacy and undesirable side-effects led us to investigate the role of Intravenous Levetiracetam in preterm neonates, the most challenging group of patients in the pediatric population. In this research highlight, we will discuss the findings of our recent in preterm neonates. Normal 0 false false false EN-US ZH-CN X-NONE MicrosoftInternetExplorer4 st1\:*{behavior:url(#ieooui) } /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman","serif";}